The facility contains around 220,500 square feet of office, manufacturing and laboratory space, including state-of-the-art technology equipped to handle process development and manufacturing of plasmids and adeno-associated virus (AAV) vectors.
The company is also offering plasmid DNA and AAV manufacturing services to external partners, with PTC championing its in-house manufacturing, research and development capabilities as offering maximum control over the quality, capacity, supply and seamless transition from clinical to commercial development.
With its global headquarters in South Plainfield, NJ, PTC Therapeutics is a biopharmaceutical company focused on innovative small molecule and gene therapies for rare genetic disorders, while it has also recently expanded into oncology and virology therapeutic research.
"We are committed to being an innovation-based company that brings the best therapies to patients with rare diseases," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, who will lead a ribbon-cutting ceremony at the site today.
"Gene therapy holds tremendous promise to treat intractable rare genetic disorders. We have built our capabilities to both perform gene therapy research and to manufacture these biological products.
"We are proud to have such a talented team and state-of-the-art manufacturing facility here in Hopewell, N.J. that will help expedite bringing these therapies to patients."
The new facility brings the total number of New Jersey-based employees at the company to 625.